drugset / Trial / NCT00195000
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out how safe and effective the combination of Mylotarg in combination with cytarabine is in treating patients with Acute Myeloid Leukemia and advanced Myelodysplastic Syndrome over the age of 60 years.
Timeline
- Start
- 2003-05
- Primary completion
- 2006-05
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Gemtuzumab Ozogamicin | Monoclonal antibody | 6 mg/m2 | Intravenous |